Adrenal insufficiency in prednisolone-treated patients with polymyalgia rheumatica or giant cell arteritis—prevalence and clinical approach
- 7 February 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 59 (10) , 2764-2773
Abstract
Objectives: Glucocorticoid treatment is fundamental in polymyalgia rheumatica (PMR) and giant cell arteritis (GCA), but carries a risk of glucocorticoid-induced adrenal insufficiency. Adrenal insufficiency can cause reluctance to stop glucocorticoid treatment after disease remission as symptoms can resemble PMR/GCA flare. We aimed to determine the prevalence of adrenal insufficiency in prednisolone-treated patients with PMR/GCA. Methods: We included 47 patients with PMR (n = 37), GCA (n = 1) or both (n = 9), treated with prednisolone for ≥5.4 months, current dose 2.5–10 mg/day. Adrenal function was evaluated using a corticotropin (Synacthen®) stimulation test following 48 h prednisolone pause. Two years’ clinical follow-up data are provided. Results: Seven patients (15%) had adrenal insufficiency, 4 (11%) of the 37 patients with PMR alone, and 3 (30%) of the 10 patients with GCA. Corticotropin-stimulated P-cortisol was significantly associated with current prednisolone dose, mean daily dose the last 3 and 6 months before testing, and basal P-cortisol, but not with total dose or treatment duration. Adrenal insufficiency occurred with all current prednisolone doses (2.5–10 mg/day). Five (71%) of the glucocorticoid-insufficient patients could discontinue prednisolone treatment; two of them recovered glucocorticoid function, whereas three still needed hydrocortisone replacement 2 years later. Two patients experienced in total four acute hospital admissions with symptoms of adrenal crises. Conclusion: Glucocorticoid-induced adrenal insufficiency occurred in 15% of patients with PMR/GCA. Mean prednisolone dose the last 3 months and basal P-cortisol were the best and simplest predictors of adrenal function. Most of the glucocorticoid-insufficient patients could discontinue prednisolone with appropriate treatment for adrenal insufficiency.Keywords
Funding Information
- The Rheumatological Research Fund
- Frederiksberg Hospital
- Skibsreder Per Henriksen R. & Hustru’s Foundation
- Eva Madura’s Foundation
- The Research Foundation of Copenhagen University Hospital
- the Novo Nordic Foundation (NNF15OC0014622)
- Oak Foundation (OCAY-13–309)
This publication has 49 references indexed in Scilit:
- Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensusAnnals of the Rheumatic Diseases, 2011
- Hypothalamus-Pituitary-Adrenal Axis Function in Patients with Rheumatoid Arthritis Treated with Nighttime-Release PrednisoneThe Journal of Rheumatology, 2010
- Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2010
- Can the prognosis of polymyalgia rheumatica be predicted at disease onset? Results from a 5-year prospective studyRheumatology, 2010
- Technical details influence the diagnostic accuracy of the 1 μg ACTH stimulation testEuropean Journal of Endocrinology, 2010
- BSR and BHPR guidelines for the management of polymyalgia rheumaticaRheumatology, 2009
- Low-dose and high-dose adrenocorticotropin testing: indications and shortcomingsCurrent Opinion in Endocrinology, Diabetes and Obesity, 2008
- Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis - A prospective two-year study in 273 patientsScandinavian Journal of Rheumatology, 2001
- The Effect of Long-Term Glucocorticoid Therapy on Pituitary–Adrenal Responses to Exogenous Corticotropin-Releasing HormoneNew England Journal of Medicine, 1992
- Corticosteroid-induced hypothalamo-pituitary-adrenal axis suppression. Prospective study using two regimens of corticosteroid therapy.Annals of the Rheumatic Diseases, 1968